SCHEMBL807185

SCHEMBL807185

CC1CC(C(C)C)CN(Cc2ccc3ccccc3n2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.43
DRD4 P21917 1/20 0.42
HCRTR1 O43613 4/20 0.40
HCRTR2 O43614 4/20 0.40
CYP1A2 P05177 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
PDE2A O00408 1/20 0.39
MCHR1 Q99705 1/20 0.38
ALOX5AP P20292 1/20 0.37
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36
GAA P10253 1/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15084352 0.88 FAAH (0.49) FAAHDRD4HCRTR1HCRTR2CYP1A2
SCHEMBL14197738 0.78 DRD4 (0.51) FAAHDRD4HCRTR1HCRTR2CYP1A2
SCHEMBL807181 0.77 DPP4 (0.47) FAAHHCRTR1HCRTR2
SCHEMBL807184 0.72 FAAH (0.45) FAAHHCRTR1HCRTR2OPRM1OPRD1
SCHEMBL6797735 0.72 FAAH (0.49) FAAHDRD4CYP1A2OPRM1OPRD1
SCHEMBL17289123 0.71 FAAH (0.65) FAAHDRD4MCHR1HTR1AHTR7
SCHEMBL1331198 0.71 FAAH (0.65) FAAHDRD4MCHR1HTR1AHTR7
SCHEMBL15081988 0.71 KDM4E (0.57) DRD4
SCHEMBL15082011 0.71 ALDH1A1 (0.45) DRD4
SCHEMBL806905 0.71 ALDH1A1 (0.45) DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242981-B2 Fused pyrazole derivatives as novel ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MERCK SHARP & DOHME LLC 2013-07-04 US disclosed
WO-2012036997-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS SCHERING CORPORATION (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172341-A1 FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS MAPK1, MAPK3, MAP3K1 FAAH 4421/4885DRD4 4754/4885HCRTR1 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.